Literature DB >> 7295472

Is the measurement of blood cimetidine levels useful?

H P Festen, J Diemel, C B Lamers, A van Schaik, A Tangerman, J H van Tongeren.   

Abstract

1 Blood cimetidine levels were measured up to 5 h after oral intake of 200 mg cimetidine with breakfast in 13 duodenal, 5 gastric and 15 anastomotic ulcer patients. 2 There were larger inter individual differences in results. The mean peak blood concentrations was 1.14 +/- 0.07 microgram/ml (range 0.54-1.94 microgram/ml), the mean period during which the blood concentration exceeded 0.5 microgram/ml was 141 +/- 11 min (range 23-306 min) and the mean area under the cimetidine blood concentration curve (AUC) was 166 +/- 8 microgram ml-1 min (range 96-280 microgram ml-1 min). Coefficient of variation of these parameters was 33%, 43% and 29% respectively. 3 There were no significant differences in these parameters between non-operated patients and patients with a partial gastrectomy. 4 In 11 patients restudied after 2 to 5 months blood cimetidine levels proved well reproducible; mean coefficient of variation of peak blood levels was 8.5 +/- 2.4%, of time during which blood levels exceeded 0.5 microgram/ml 7.6 +/- 2.5% and of the AUC 5.0 +/- 1.0%. 5 There was no difference in peak blood levels, duration of blood level exceeding 0.5 microgram/ml and blood cimetidine AUC between 24 patients healed after 4 weeks cimetidine therapy and 9 in whom healing took longer. Likewise, there was no evidence of lower blood cimetidine concentrations in 9 patients who relapsed during maintenance cimetidine treatment compared with 24 who did not relapse.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295472      PMCID: PMC1401794          DOI: 10.1111/j.1365-2125.1981.tb01237.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Inhibition of food-stimulated gastric acid secretion by cimetidine.

Authors:  R E Pounder; J G Williams; R C Russell; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1976-03       Impact factor: 23.059

2.  [Suppression of gastric acid production using cimetidine; results of a double-blind study of the significance of cimetidine for the treatment of peptic ulcers].

Authors:  H P Festen; C B Lamers; J H van Tongeren
Journal:  Ned Tijdschr Geneeskd       Date:  1978-06-17

3.  The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.

Authors:  G Bodemar; B Norlander; L Fransson; A Walan
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

4.  Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.

Authors:  A Somogyi; H G Rohner; R Gugler
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

5.  Blood level of cimetidine in relation to age.

Authors:  A Redolfi; E Borgogelli; E Lodola
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

6.  Clinical and pharmacological effectiveness of cimetidine in duodenal ulcer patients.

Authors:  S J Ruen; P Hesselfeldt; N E Larsen
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

7.  Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.

Authors:  R M Henn; J I Isenberg; V Maxwell; R A Sturdevant
Journal:  N Engl J Med       Date:  1975-08-21       Impact factor: 91.245

8.  Cimetidine in anastomotic ulceration after partial gastrectomy.

Authors:  H P Festen; C B Lamers; W M Driessen; J H Van Tongeren
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

9.  Cimetidine treatment of duodenal ulceration: short term clinical trial and maintenance study.

Authors:  D J Hetzel; P J Hansky; D J Shearman; M G Korman; R Hecker; G J Taggart; R Jackson; B W Gabb
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

10.  Cimetidine: an advance in gastric ulcer treatment?

Authors:  A G Morgan; W A McAdam; C Pacsoo; B E Walker; A V Simmons
Journal:  Br Med J       Date:  1978-11-11
View more
  6 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Refractory duodenal ulcer.

Authors:  K D Bardhan
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

Review 3.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 5.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

6.  Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists.

Authors:  R Gugler; J C Jensen; H G Rohner; P Reimnitz; A Somogyi
Journal:  Klin Wochenschr       Date:  1985-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.